2024年8月12日 · Dengvaxia is the only dengue vaccine approved by the U.S. Food and Drug Administration and recommended for routine use by the Advisory Committee on Immunization Practices. It is made by Sanofi Pasteur. The vaccine prevents dengue caused by all four dengue virus serotypes.

Dengvaxia is a chimeric vaccine made using recombinant DNA technology by replacing the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine with those from the four dengue serotypes.

2023年8月8日 · For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous...

2025年1月30日 · Dengvaxia is the only dengue vaccine currently available in the United States. Dengvaxia is recommended to prevent dengue in children aged 9–16 years, with laboratory-confirmed previous dengue virus infection and living in areas where dengue is common.

2024年5月10日 · Two dengue vaccines have been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur, and Qdenga® (TAK-003), developed by Takeda. Another dengue vaccine developed at the Laboratory of Infectious Diseases, at the National Institutes of Allergy and Infectious Diseases (NIAID) in the United States, is in the late stages of clinical development.

Explore comprehensive information on the Sanofi Dengvaxia® vaccine, including usage, efficacy and safety evaluations and approval for use around the world.

2024年8月12日 · The Dengvaxia dengue vaccine requires three doses for full protection. The vaccine doses are given 6 months apart. Dengvaxia is administered subcutaneously.

The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and...